EASD 2017

​53rd Annual Meeting of the European Association for the Study of Diabetes, 11-15 September 2017, Lisbon, Portugal.

A. Ali, N. Safai, P. Rossing, M. Ridderstråle; Cluster analyses of patients with dysregulated type 2 diabetes based on routine clinical markers reveal cluster-specific prevalence of diabetes complications, September 13, 2017, 12:00 - 1:00 PM, Poster Hall. 53rd EASD Annual Meeting, Lisbon, Portugal, 2017.
Abstract 1028.

A.R. Lanng, L.S. Gasbjerg, N.C. Bergmann, T. Vilsbøll, F.K. Knop; Beta cell secretory responses to oral ethanol and isoethanolaemic i.v. ethanol in healthy subjects. September 12, 2017, 12:00 - 1:00 PM, Poster Hall, 53rd EASD Annual Meeting, Lisbon, Portugal, 2017. Abstract 487.


A. Brønden, A. Albér, U. Rohde, J.F. Rehfeld, J.J. Holst, T. Vilsbøll, F.K. Knop;  Metformin potentiates bile acid-induced GLP-1 secretion in patients with type 2 diabetes. September 15, 2017, 11:15 - 11:30 AM, Roma Hall, 53rd EASD Annual Meeting, Lisbon, Portugal, 2017. Abstract 442.


A.B. Lund, M.F. Grøndahl, J.I. Bagger, J.J. Holst, M. Christensen, T. Vilsbøll, F.K. Knop. Glucagon elimination is increased in patients with type 2 diabetes. 526 - Glucagon elimination is increased in patients with type 2 diabetes. September 14, 2017, 1:15 - 2:15 PM, Poster Hall, 53rd EASD Annual Meeting, Lisbon, Portugal, 2017. Abstract 526.

A. Consoli, S.C. Bain, M. Davies, I. Lingvay, E.Q. Bergan, O. Hansen, T. Vilsbøll. Semaglutide provides sustained reductions in body weight over 2 years in subjects with type 2 diabetes (SUSTAIN 6). 53rd EASD Annual Meeting, Lisbon, Portugal, 2017. Diabetologia 2017, 60(S1): Abstract 4.

B. Carstensen, M.E. Jørgensen; Predicting total burden of diabetes in Denmark till 2030. Poster.  September 12, 2017, 12:00 - 1:00 PM, Poster Hall, 53rd EASD Annual Meeting, Lisbon, Portugal, 2017. Abstract 366.

C.S. Hansen, C.S. Frandsen, J. Fleischer, D. Vistisen, L. Tarnov, F.K. Knop, S. Madsbad, H.U. Andersen, T.F. Dejgaard; Autonomic regulation may modify the weight reducing effect of liraglutide in overweight patients with type 1 diabetes, September 13, 2017, 1:15 - 2:15 PM, Poser Hall, 53rd EASD Annual Meeting, Lisbon, Portugal, 2017. Abstract 831.


C.T.B. Juel, A. Lund, C.P. Hansen, J. Storkholm, N. Wewer Albrechtsen, J. Holst, T. Vilsbøll, F.K. Knop; The glucagon-like peptide-1 receptor agonist lixisenatide reduces postprandial glucose excursions in totally pancreatectomised patients. September 13, 2017, 1:15 - 2:15 PM, Poster Hall, 53rd EASD Annual Meeting, Lisbon, Portugal, 2017. Abstract 516.


D. Grabowski, K. Olesen, M.R. Reino, T.H. Andersen; Family dialogue tools: how can healthcare professionals facilitate mutual involvement in families dealing with type 2 diabetes,  September 12, 2017, 12:00 - 1:00 PM, Poster Hall,  53rd EASD Annual Meeting, Lisbon, Portugal, 2017. Abstract 744.


E. Nielsen-Hannerup, S. Hædersdal, A. Lund, H.E.G. Maagensen, J.J. Holst, F.K. Knop, T. Vilsbøll; The role of glucagon in gastrointestinal-mediated glucose-disposal and incretin effect in patients with type 2 diabetes and normal glucose tolerant individuals. September 14, 2017, 1:15 - 2:15 PM, Poster Hall, 53rd EASD Annual Meeting, Lisbon, Portugal, 2017. Abstract 524.


E.L. Larsen, S. Foghsgaard, L. Vedtofte, E.R. Mathiesen, P. Damm, J.A. Svare, T.D. Clausen, T. Henriksen, H.E. Poulsen, F.K. Knop, T. Vilsbøll; The effect of liraglutide on oxidative nucleic acid modifications in women with prior gestational diabetes. September 13, 2017, 1:15 - 2:15 PM, Poster Hall, 53rd EASD Annual Meeting, Lisbon, Portugal, 2017. Abstract 828.

F. Persson, J. Bodegard, T. Nyström, D. Nathanson, M. Thuresson, M. Linnemann Jensen, M.E. Jørgensen, K.I. Birkeland, H.L. Gulseth, A. Norhammar, J.W. Eriksson;
Second line treatment after metformin monotherapy of type 2 diabetes in a real life setting 2006 to 2015: nationwide data comparison between Denmark, Norway and Sweden, Sep. 13, 2017, 1:15 - 2:15 PM, Poster Hall, 53rd EASD Annual Meeting, Lisbon, Portugal, 2017. Abstract 660.


H. Maagensen
, A.E. Junker, N.R. Jørgensen, L.L. Gluud, F.K. Knop, T. Vilsbøll; Role of the gut in glucose-induced suppression of bone resorption in patients with non-alcoholic fatty liver disease and/or type 2 diabetes. September 13, 2017, 1:15 - 2:15 PM, Poster Hall, 53rd EASD Annual Meeting, Lisbon, Portugal, 2017. Abstract 1239.

J.A. Davidson, V.R. Aroda, B.W. Bode, H.W. Rodbard, A. Andersen, A. Kaas, T. Vilsbøll. Insulin degludec/liraglutide (IDegLira) is efficacious and safe in patients with type 2 diabetes with normal, mild or moderate renal impairment: analyses from phase 3 trials. 53rd EASD Annual Meeting, Lisbon, Portugal, 2017. Diabetologia 2017, 60(S1): Abstract 809

J.I. Bagger, A.B. Lund, N.J. Wewer Albrechtsen, M. Christensen, M.F. Grøndahl, C.P. Hansen, J. Storkholm, J.J. Holst4, T. Vilsbøll, F.K. Knop; Increased liver fat content in totally pancreatectomised patients. September 14, 2017, 12:00 - 1:00 PM,  Poster Hall, 53rd EASD Annual Meeting, Lisbon, Portugal, 2017. Abstract1243.

J. Øllgaard, P. Gæde, R. Rørth, P. Rossing, L. Køber, H. Parving, O. Pedersen;
Risk of heart failure in intensively treated patients with type 2 diabetes and microalbuminuria: 21 years follow-up in the multifactorial Steno-2 intervention,  September 13, 2017, 10:15 - 10:30 AM  Puccini Hall, 53rd EASD Annual Meeting, Lisbon, Portugal, 2017. Abstract 85.

K. Faerch, M. Alssema, D. Mela, R. Borg, H. Zheng, D. Nathan, D. Vistisen; Relative contributions of fasting and postprandial glycaemia to HbA1c among persons with normal, pre-diabetes and diabetes HbA1c levels, September 12, 2017, 12:00 - 1:00 PM, Poster Hall, 53rd EASD Annual Meeting, Lisbon, Portugal, 2017. Abstract 265.


K. Olesen, B. Cleal, T. Skinner. Willaing; Non-disclosure of type 2 diabetes at work among Danish employees, September 13, 2017, 1:15 - 2:15 PM, Poster Hall, 53rd EASD Annual Meeting, Lisbon, Portugal, 2017. Abstract 771.

L. Bjerg, A. Hulman, M. Charles, B. Carstensen, M.E. Jørgensen, D.R. Witte; Mortality rate in patients with type 1 diabetes with multiple micravascular complications

L. Vedtofte, E. Hannerup, S. Foghsgaard, E.R. Mathiesen, T. Buhl, L.K. Christiansen, J.A. Svare, T.D. Clausen, P. Damm, N.R. Jørgensen, F.K. Knop, T. Vilsbøll; Bone turnover in women with prior gestational diabetes after 52 week's treatment with liraglutide. September 14, 2017, 10:30 - 10:45 AM, Roma Hall, 53rd EASD Annual Meeting, Lisbon, Portugal, 2017. Abstract 146.   


L.S. Gasbjerg, A.R. Lanng, B. Hartmann, A.H. Sparre-Ulrich, F. Dela, M. Christensen, J.J. Holst, T. Vilsbøll, M.M. Rosenkilde, F.K. Knop; GIP(3-30)NH2 is an efficacious GIP receptor antagonist in humans. September 14, 2017, 3:45 - 4:00 PM, Puccini Hall, 53rd EASD Annual Meeting, Lisbon, Portugal, 2017. Abstract 198.

M.A. Cavender, A. Norhammar, K.I. Birkeland, M.E. Jørgensen, J.P. Wilding, K. Khunti, A.Z. Fu, J. Bodegård, B. Blak, E.T. Wittbrodt, M. Thuresson, P. Fenici, N. Hammar, M. Kosiborod, on behalf of the CVD-REAL Investigators and StudyGroup; Hospitalisation for heart failure and death in new users of SGLT-2 inhibitors in patients with and without cardiovascular disease: the CVD-REAL study,  September 13, 2017, 11:00 - 11:15 AM, 53rd EASD Annual Meeting, Lisbon, Portugal, 2017. Abstract 88.

M.A. Nexo, K. Carlsen, J. Pedersen, T. Watt, S.M. Hansen, J.B. Bjorner, Long term sickness absence in diabetes- A Danish register-based longitudinal study with up to 17 years followup’   September 12, 2017, 1:15 - 2:15 PM  Poster Hall, 53rd EASD Annual Meeting, Lisbon, Portugal. Abstract 755.


M.E. Jørgensen, B. Carstensen; Estimates of pre-diabetes and undiagnosed diabetes in Denmark. September 12, 2017, 12:00 - 1:00 PM, Poster Hall, 53rd EASD Annual Meeting, Lisbon, Portugal, 2017. Abstract 368.

M. Frimodt-Møller, B. von Scholten, H. Reinhard, T.W. Hansen, F. Persson, H.-H. Parving, P. Rossing; GDF-15 and FGF-23 are associated with mortality in type 2 diabetic patients with microalbuminuria,  September 12, 2017, 12:00 - 1:00 PM  Poster Hall, 53rd EASD Annual Meeting, Lisbon, Portugal, 2017. Abstract 1113.

M. Kosiborod, M.A. Cavender, A.Z. Fu, A. Norhammar, K.I. Birkeland, M. Jørgensen, R.W. Holl, N. Hammar, E.T. Wittbrodt, J. Bodegård, M. Scheerer, M. Thuresson, P. Fenici, on behalf of the CVD-REAL Investigators and StudyGroup; Total events of hospitalisation for heart failure in new users of SGLT-2 inhibitors: real world data from 5 countries and more than 298,000 patients: the CVD-REAL study, September 13, 2017, 11:15 - 11:30 AM  Puccini Hall, 53rd EASD Annual Meeting, Lisbon, Portugal, 2017. Abstract 89.

M.M.B. Christensen, E.E. Hommel, M.E. Jørgensen, B.J. von Scholten, C.S. Hansen; Prevalence of diabetic neuropathy in adolescents with type 1 diabetes and the association to insulin pump therapy, September 12, 2017, 1:15 - 2:15 PM Poster Hall, 53rd EASD Annual Meeting, Lisbon, Portugal, 2017. Abstract 967.


N.C. Bergmann, A. Lund, L.S. Gasbjerg, E.C.E. Meessen, L. Jessen, M. Christensen, T. Vilsbøll, F.K. Knop; The effects of GIP/GLP-1 receptor co-activation on appetite and food intake in overweight/obese subjects.September 12, 2017, 11:15 - 11:30 AM, Roma Hall, 53rd EASD Annual Meeting, Lisbon, Portugal, 2017. Abstract 5.    

N. Safai, A. Ali, T.R.L. Suvitaival, P. Spegel, M. Al-Majdoub, B. Carstensen, H. Vestergaard, M. Ridderstråle, CIMT Trial Group; Changes in metabolites in response to metformin during the 18-month Copenhagen Insulin and Metformin Therapy (CIMT) Trial,  September 12, 2017, 12:00 - 1:00 PM, Poster Hall,  53rd EASD Annual Meeting, Lisbon, Portugal, 2017.  Abstract 908.

N. Tofte
, on behalf of the PRIORITY study group; Baseline characteristics in PRIORITY study: proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in type 2 diabetes, September 14, 2017, 1:15 - 2:15 PM, Poster Hall,  53rd EASD Annual Meeting, Lisbon, Portugal, 2017. Abstract 1052.


P. Mensberg
, E. Espersen, K.A. Sjøberg, H. Storgaard, N.R. Jørgensen, S. Nyby, B. Kiens, E.A. Richter, F.K. Knop, T. Vilsbøll. 823 - The effect of liraglutide on bone turnover during exercise training in patients with type 2 diabetes. September 13, 2017, 1:15 - 2:15 PM, Poster Hall, 53rd EASD Annual Meeting, Lisbon, Portugal, 2017. Abstract 823.

P.Rossing - REMOVAL: a randomized controlled trial of metformin in adults with type 1 diabetes, September 10 2017 2:00 p.m.- 4:00 p.m. (time to be confirmed), 53rd EASD Annual Meeting, Lisbon, Portugal, 2017.    

S.A. Winther, M. Frimodt-Møller, E.H. Zobel, T.W. Hansen, P. Rossing; Reduced sublingual endothelial glycocalyx in type 1 diabetic patients with diabetic nephropathy,  September 13, 2017, 12:00 - 1:00 PM, Poster Hall,  53rd EASD Annual Meeting, Lisbon, Portugal, 2017.  Abstract 1084.


S. Engberg,
H. Andersen, K. Kirketerp-Moeller, A. Rasmussen ; Incidence and predictors of recurrent and new diabetic foot ulcers, September 14, 2017, 1:15 - 2:15 PM, Poster Hall, 53rd EASD Annual Meeting, Lisbon, Portugal, 2017. Abstract 999. 


S. Foghsgaard, L. Vedtofte, E. Bahne, C. Andreasen, L.K. Christiansen, J.A. Svare, T.D. Clausen, E.R. Mathiesen, P. Damm, L.L. Gluud, F.K. Knop, T. Vilsbøll; Is double-blinding achievable in a placebo-controlled trial with the glucagon-like-peptide-1 receptor agonist liraglutide? September 12, 2017, 1:15 - 2:15 PM, Poster Hall, 53rd EASD Annual Meeting, Lisbon, Portugal, 2017. Abstract 802.

S.S. Torekov, C. Janus, H. Amadid, D. Vistisen, D. Witte, A. Jonsson, T. Lauritzen, S. Brage, O. Pedersen, A.-L. Bjerregaard, T. Hansen, J. Holst, M. Jørgensen, K. Færch; Associations of physical activity intensity levels and cardiorespiratory fitness with glucose-induced GLP-1 responses: the ADDITTION-PRO study,  September 14, 2017, 12:00 - 1:00 PM, Poster Hall, 53rd EASD Annual Meeting, Lisbon, Portugal, 2017. Abstract 519.

T. Hansen, E. Zobel, B.J. von Scholten, H. Reinhard, F. Persson, T. Teerlink, H.-H. Parving, P.K. Jacobsen, P. Rossing; Symmetric and asymmetric dimethylarginine as risk markers of cardiovascular disease, mortality and deterioration in kidney function in patients with type 2 diabetes, September 12, 2017, 12:00 - 1:00 PM, Poster Hall, 53rd EASD Annual Meeting, Lisbon, Portugal, 2017. Abstract 1108.

T. Vilsbøll, T. Blevins, B.W. Bode, L.A. Leiter, N. Poulter, J. Thurman, B.F.R. Agner, L. Lehmann, E. Jaeckel. IDegLira improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin: analyses of DUAL II and DUAL V. 53rd EASD Annual Meeting, Lisbon, Portugal, 2017. Diabetologia 2017, 60(S1): Abstract 113


Redaktør